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iate p value for the coefficient of LDL on treatment (p  0.26).
This model suggests that age is more predictive of cancer
incidence than LDL on treatment. Based on this analysis, we
should reconsider the assertion that statin-induced lowering of
LDL is associated with increased cancer incidence.
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Risk Associated
With Statin Treatment
Several prospective, randomized, placebo-controlled trials have
established the fundamental preventive role of statins in the
treatment of atherosclerotic disease, including coronary artery
disease, stroke, and peripheral artery disease. However, in high-
risk cohorts of elderly, hypertensive patients and patients with
heart failure, low cholesterol portends a poor prognosis (1,2). This
controversial association has been ascribed to the role of cholesterol
as a marker of incipient risk, which disappears after accounting for
the early deaths (3). In their retrospective meta-analysis of statin
users in large randomized, controlled trials, Alsheikh-Ali et al. (4)
observed an association between statin-induced lowering of low-
density lipoprotein and increased risk of cancer, and they con-
cluded that this may offset some of the benefits of statins. Their
conclusion of a relationship is most likely spurious and dependent
on an association between incipient cancer risk and attainment of
low levels of low-density lipoprotein. Unfortunately, they only
reported on the statin groups. It would have been helpful if they
excluded a similar association among the placebo groups and if
they had presented data excluding deaths within the first year after
onset of statin treatment, which may be confounders. In the
longest follow-up of any statin trial, 4S (Scandinavian Simvastatin
Survival Study) demonstrated that after 10 years there was a
nonsignificant trend toward less cancer among patients who
received simvastatin treatment during the trial period (5).
*John Kjekshus, MD, PhD
*Department of Cardiology
Rikshospitalet University Clinic
University of Oslo
Sognsvannsveien 20
0027 Oslo
Norway
E-mail: john.kjekshus@medicin.uio.no
doi:10.1016/j.jacc.2007.08.056
REFERENCES
1. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low
serum total cholesterol is associated with marked increase in mortality in
advanced heart failure. J Card Fail 2002;8:216–24.
2. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between
cholesterol and survival in patients with chronic heart failure. J Am Coll
Cardiol 2003;43:1933–40.
3. Corti M-C, Guralnik JM, Salive ME, et al. Clarifying the direct
relation between total cholesterol levels and death from coronary heart
disease in older persons. Ann Intern Med 1997;126:153–60.
4. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the
magnitude of lipid lowering on risk of elevated liver enzymes, rhabdo-
myolysis, and cancer. J Am Coll Cardiol 2007;50:409–18.
5. Strandberg TE, Pyörälä K, Cook TJ, et al. Mortality and incidence of
cancer during 10-year follow-up of the Scandinavian Simvastatin
Survival Study. Lancet 2004;364:771–7.
Low Low-Density Lipoprotein
Cholesterol and Cancer Risk
The central finding in the report by Alsheikh-Ali et al. (1) was
Figure 9, which suggested a relationship between achieved low-
density lipoprotein (LDL) cholesterol and newly diagnosed can-
cers in 13 arms of statin trials. I suggest that the relationship is
confounded by age in various trials. The authors accounted for
sample size, but seemingly not for age, which is a bit surprising, as
age-adjustment is one of the most frequent procedures in epide-
miologic research. Are there some specific reasons for not doing
so? In any case, reasons are not stated.
Figure 1 Dependence of Yearly Cancer Incidence
on Age in Patients Treated With Statins
Cancer incidence was calculated from data provided in Alsheikh-Ali et al. (1).
AFCAPS  Air Force Texas Coronary Atherosclerosis Prevention Study;
ALLHAT  Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial; CARE  Cardiac Angiography in REnally impaired patients; HPS 
Medical Research Council/British Heart Foundation Heart Protection Study;
LIPID  Long-Term Intervention With Pravastatin in Ischemic Disease Trial;
PROSPER  Prospective Study of Pravastatin in the Elderly at Risk; WOS 
West of Scotland trial; 4S  Scandinavian Simvastatin Survival Study.
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Consequently, I made further simple calculations based on
Table 2 in the study by Alsheikh-Ali et al. (1). There was a
significant correlation between achieved LDL and cancer per
100,000 person-years (r  0.75, p  0.003), but also between
mean age in trials (median age 65 years for the HPS [Heart
Protection Study]) and cancer incidence (r  0.82, p  0.0006).
This is naturally expected as cancer risk increases with age. In
multivariate analyses, adjusted for sample size, achieved LDL was
a significant predictor of cancer incidence (p  0.03). However,
when age was included in the model, age (p  0.008)—but not
achieved LDL (p  0.42)—was a significant predictor of cancer
risk.
I think that these findings, together with totality of evidence
including data from the TNT (Treating to New Targets) study (2)
and also from the IDEAL (Incremental Decrease in Clinical
Endpoints Through Aggressive Lipid Lowering) study (3), at this
stage refute a true link between achieved LDL and cancer risk.
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Reply
Drs. Rembold and Strandberg appropriately raise the possibility
of confounding by age as an explanation for the observed
association between achieved low-density lipoprotein choles-
terol (LDL-C) and incident cancer (1). To properly address
that possibility, we performed a more comprehensive analysis
including all the trials in the original study with the addition of
5 large randomized statin trials where incident cancer was
reported (Post-CABG [Post Coronary Artery Bypass Graft],
GISSI—Prevenzione [Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto Miocardico—Prevention], Kyushu
Lipid Intervention, ALERT [Assessment of Lescol in Renal
Transplantation], and MEGA [Management of Elevated Cho-
lesterol in the Primary Prevention Group of Adult Japanese])
(2– 6). Furthermore, the analysis we performed was weighted
and used a random-effects model given the heterogeneity of
the trials involved. This more appropriate and comprehensive
analysis yields a significant univariate association between age
and incident cancer (p  0.031) as well as a significant inverse
univariate association between achieved LDL-C and cancer
(p  0.006). When age and achieved LDL-C are combined in
a multivariate model, the inverse association between achieved
LDL-C and cancer persists (p  0.021), whereas that between
age and cancer loses statistical significance (p  0.110). This
suggests that the association between achieved LDL-C and
cancer is not confounded by age, a finding consistent with
previous epidemiologic observations (7). Dr. Kjekshus suggests
excluding deaths within the first year after onset of statin
treatment to test the hypothesis that the observed relationship
is dependent on an association between incipient cancer and low
levels of LDL-C. Although such an analysis would be infor-
mative, we are unable to perform it because we have no access
to individual patient data or dates of cancer diagnoses. Further-
more, it is worth noting that the association between low
cholesterol and cancer deaths in the epidemiologic literature
persisted after excluding deaths occurring in the first 5 years
after measuring cholesterol levels (7). We also agree that a
comparative analysis including the placebo groups would be
informative, and this is part of ongoing analyses to better
understand the association between LDL-C and cancer.
Alawi A. Alsheikh-Ali, MD
*Richard H. Karas, MD, PhD
*Molecular Cardiology Research Center
Tufts-New England Medical Center
New England Medical Center
750 Washington Street
Box 80
Boston, Massachusetts 02111
E-mail: rkaras@tufts-nemc.org
doi:10.1016/j.jacc.2007.09.024
REFERENCES
1. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the
magnitude of lipid lowering on risk of elevated liver enzymes, rhabdo-
myolysis, and cancer: insights from large randomized statin trials. J Am
Coll Cardiol 2007;50:409–18.
2. The Post Coronary Artery Bypass Graft Trial Investigators. The effect
of aggressive lowering of low-density lipoprotein cholesterol levels and
low-dose anticoagulation on obstructive changes in saphenous-vein
coronary-artery bypass grafts. N Engl J Med 1997;336:153–62.
3. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto Miocardico). Results of the low-dose (20 mg)
pravastatin GISSI Prevenzione trial in 4271 patients with recent
myocardial infarction: do stopped trials contribute to overall knowledge?
Ital Heart J 2000;1:810–20.
4. The Kyushu Lipid Intervention Study Group. Pravastatin use and risk
of coronary events and cerebral infarction in Japanese men with
moderate hypercholesterolemia: the Kyushu Lipid Intervention study. J
Atheroscler Thromb 2000;7:110–21.
5. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on
cardiac outcomes in renal transplant recipients: a multicentre, random-
ised, placebo-controlled trial. Lancet 2003;361:2024–31.
6. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of
cardiovascular disease with pravastatin in Japan (MEGA study): a
prospective randomised controlled trial. Lancet 2006;368:1155–63.
7. Jacobs D, Blackburn H, Higgins M, et al. Report of the Conference on
Low Blood Cholesterol: mortality associations. Circulation 1992;86:
1046–60.
92 Correspondence JACC Vol. 51, No. 1, 2008
January 1/8, 2008:89–92
